Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 4:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Coronary Restenosis Clear all
Terminated Phase 2Phase 3 Interventional Results available

Radiation Following Percutaneous Balloon Aortic Valvuloplasty to Prevent Restenosis

NCT00538759
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
External beam radiation therapy, Sham Control
Device · Other
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
75 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Minneapolis, Minnesota • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 29, 2026, 4:50 PM EDT
Completed Not applicable Interventional

In Stent ELUTES Study

NCT00225680
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
drug eluting coronary stent
Device
Lead sponsor
Cook Group Incorporated
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Sep 29, 2026, 4:50 PM EDT
Recruiting Not applicable Interventional

Virtue® SAB in the Treatment of Coronary ISR Trial

NCT07045194
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Virtue Sirolimus AngioInfusion Balloon, AGENT™ Paclitaxel Drug-Coated Balloon
Device
Lead sponsor
Orchestra BioMed, Inc
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
15
States / cities
Gainesville, Florida • Pensacola, Florida • Indianapolis, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 29, 2026, 4:50 PM EDT
Completed Phase 2Phase 3 Interventional

Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis

NCT00287573
View directory record Official record
Conditions
Coronary Restenosis
Interventions
TAXUS Express2, Brachytherapy (beta source)
Device · Procedure
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
40
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2010 · Synced Sep 29, 2026, 4:50 PM EDT
Completed No phase listed Observational Results available

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study

NCT01249027
View directory record Official record
Conditions
Angioplasty, Chronic Coronary Occlusion, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
2,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Sep 29, 2026, 4:50 PM EDT
Completed Not applicable Interventional Results available

Absorb IV Randomized Controlled Trial

NCT02173379
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Absorb BVS, XIENCE
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
98
States / cities
Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Sep 29, 2026, 4:50 PM EDT
Active, not recruiting Not applicable Interventional

SELUTION SLR™ 014 In-stent Restenosis

NCT04280029
View directory record Official record
Conditions
Coronary Restenosis
Interventions
SELUTION SLR 014 DEB, Standard of Care
Device
Lead sponsor
M.A. Med Alliance S.A.
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
34
States / cities
Loma Linda, California • Los Angeles, California • Torrance, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 29, 2026, 4:50 PM EDT
Completed Phase 4 Interventional

Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty

NCT00162357
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Coronary Restenosis
Interventions
Technetium Tc99m Sestamibi
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
21 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
7
States / cities
Hartford, Connecticut • Waterbury, Connecticut • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Sep 29, 2026, 4:50 PM EDT
Not listed Phase 2Phase 3 Interventional

PROVIDENCE:Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With Coronary Lesions

NCT00116792
View directory record Official record
Conditions
Coronary Artery Disease, Diabetes Mellitus
Interventions
Percutaneous Coronary Intervention (PCI)
Procedure
Lead sponsor
Gold, Herman K., MD
Individual
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2007 · Synced Sep 29, 2026, 4:50 PM EDT
Completed No phase listed Observational

The SCRIPPS DES REAL WORLD Registry

NCT00714623
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Restenosis, Coronary Thrombosis
Interventions
Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)
Device
Lead sponsor
Paul S Teirstein, MD
Other
Eligibility
18 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2012 · Synced Sep 29, 2026, 4:50 PM EDT
Completed Phase 2 Interventional

A Safety Study of ABI-007 for In-Stent Restenosis

NCT00093223
View directory record Official record
Conditions
Angina Pectoris, Coronary Artery Disease
Interventions
Paclitaxel Nanoparticle Albumin Bound
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 29, 2026, 4:50 PM EDT
Completed Phase 3 Interventional Results available

SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System

NCT00307047
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
XIENCE V® Everolimus Eluting Coronary Stent, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
3,687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
65
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Fairfax, California + 54 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Sep 29, 2026, 4:50 PM EDT
Completed Not applicable Interventional Results available

A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)

NCT01923740
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
XIENCE V EECSS, Absorb BVS System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 29, 2026, 4:50 PM EDT
Completed Phase 2Phase 3 Interventional

Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions

NCT00301522
View directory record Official record
Conditions
Coronary Stenosis
Interventions
TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation, Express2
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 58 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2010 · Synced Sep 29, 2026, 4:50 PM EDT
Completed No phase listed Observational Results available

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)

NCT00676520
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
XIENCE V® Everolimus Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
8,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Sep 29, 2026, 4:50 PM EDT
Completed No phase listed Observational

Whole Genome Association Study to Identify and Validate Genes for Restenosis: CardioGene Validation Proposal

NCT00589810
View directory record Official record
Conditions
Coronary Restenosis
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
761 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Sep 29, 2026, 4:50 PM EDT
Completed Phase 3 Interventional

Sirolimus-Eluting Stent vs. Intravascular Brachytherapy in In-Stent Restenotic Coronary Artery Lesions(SISR)

NCT00231257
View directory record Official record
Conditions
In-Stent Restenosis
Interventions
Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent, Brachytherapy
Device · Procedure
Lead sponsor
Cordis US Corp.
Industry
Eligibility
18 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 18, 2009 · Synced Sep 29, 2026, 4:50 PM EDT
Completed Not applicable Interventional

V-Flex Plus PTX Drug Eluting Coronary Stent

NCT00225693
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
drug eluting coronary stent
Device
Lead sponsor
Cook Group Incorporated
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Sep 29, 2026, 4:50 PM EDT
Terminated Not applicable Interventional Results available

SOLEMN Study - Synergy Optical Coherence Tomography in Left Main PCI

NCT03474432
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Optical Coherence Tomography, In-stent Coronary Artery Restenosis
Interventions
Optical Coherence Tomography
Device
Lead sponsor
Jesse Brown VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Sep 29, 2026, 4:50 PM EDT
Completed Phase 3 Interventional Results available

SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

NCT00180479
View directory record Official record
Conditions
Stents, Coronary Artery Disease, Total Coronary Occlusion, Coronary Artery Restenosis, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
Interventions
XIENCE V® Everolimus Eluting Coronary Stent, TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 56 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Sep 29, 2026, 4:50 PM EDT
Completed No phase listed Observational Results available

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)

NCT01120379
View directory record Official record
Conditions
Chronic Coronary Occlusion, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
XIENCE V® EECSS
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
5,034 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2015 · Synced Sep 29, 2026, 4:50 PM EDT
Completed Phase 4 Interventional

Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside)

NCT00963781
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Thrombosis
Interventions
Medtronic Endeavor Stent, Reduced duration (6 months) DAPT
Device · Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 29, 2026, 4:50 PM EDT
Completed Not applicable Interventional Results available

Carotid Revascularization Endarterectomy Versus Stenting Trial

NCT00004732
View directory record Official record
Conditions
Atherosclerosis, Stroke, Carotid Stenosis, Cerebral Infarction, Myocardial Infarction
Interventions
Carotid Endarterectomy (CEA), Carotid Artery Stenting (CAS)
Procedure · Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
2,502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2016
U.S. locations
106
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Sep 29, 2026, 4:50 PM EDT
Terminated Phase 2 Interventional

Serp-1 for the Treatment of Acute Coronary Syndrome

NCT00243308
View directory record Official record
Conditions
Unstable Angina, Coronary Atherosclerosis, Coronary Restenosis
Interventions
Serine proteinase-1 (Serp-1)
Drug
Lead sponsor
Viron Therapeutics Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Gainesville, Florida • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 5, 2009 · Synced Sep 29, 2026, 4:50 PM EDT